Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR 325.75
-9.95 (-2.96%)
Apr 24, 2025, 3:30 PM IST
Biocon Revenue
Biocon had revenue of 38.21B INR in the quarter ending December 31, 2024, a decrease of -3.35%. This brings the company's revenue in the last twelve months to 147.62B, up 1.02% year-over-year. In the fiscal year ending March 31, 2024, Biocon had annual revenue of 147.56B with 32.05% growth.
Revenue (ttm)
147.62B
Revenue Growth
+1.02%
P/S Ratio
2.65
Revenue / Employee
9.05M
Employees
16,315
Market Cap
391.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | 63.01B | 7.86B | 14.26% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Biocon News
- 21 hours ago - Biocon to raise Rs 4,500 crore via QIP or other routes - Business Upturn
- 1 day ago - Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report - Business Upturn
- 4 days ago - Biocon shares in focus ahead of April 23 board meeting to consider fundraise proposal - Business Upturn
- 9 days ago - Biocon shares jump 3% as its subsidiary secures US market entry for Yesafili - Business Upturn
- 9 days ago - Biocon Biologics secures U.S. market entry for Yesafili™, an interchangeable biosimilar to Eylea® - Business Upturn
- 13 days ago - Biocon shares rise over 3% as USFDA approves bevacizumab biosimilar Jobevne™ for cancer treatment - Business Upturn
- 13 days ago - Top stocks to watch today, April 11: Tata Steel, Infosys, TCS, BHEL, Aurobindo Pharma, Biocon and more - Business Upturn
- 14 days ago - Biocon Biologics receives U.S. FDA approval for bevacizumab biosimilar JOBEVNE - Business Upturn